State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
Latest action · May 15, 2019 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 2, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
This bill authorizes health insurance issuers to jointly negotiate the prices for prescription drugs with the manufacturers of such drugs.
Cosponsors 2
Members who signed on, in the order they did. Signatures ran from Apr 15, 2019 to Oct 17, 2019.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-NC | Ted Budd | Apr 15, 2019 | |
| R-AZ | Debbie Lesko | Oct 17, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Judiciary Committee | Referred Apr 2, 2019 |
| Administrative State, Regulatory Reform, and Antitrust Subcommittee | Referred May 15, 2019 |
Actions 3
Everything that happened, newest first.
- May 15, 2019Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- Apr 2, 2019Introduced in House
- Apr 2, 2019Referred to the House Committee on the Judiciary.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 57, April 2, 2019, page H2987.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 4796 | Fair Care Act of 2020 | Related bill | Oct 5, 2020 |
| HR 8527 | Fair Care Act of 2020 | Related bill | Oct 2, 2020 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes.
- Short Title(s) as Introduced
- State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Cancer
- Child health
- Child safety and welfare
- Congressional oversight
- Drug, alcohol, tobacco use
- Health
- Health care costs and insurance
- Health care coverage and access
- Health facilities and institutions
- Health personnel
- Health programs administration and funding
- Long-term, rehabilitative, and terminal care
- Prescription drugs
- Rural conditions and development
- Sales and excise taxes
- State and local finance
Text 1
Each version as it was printed, newest first.
- Apr 2, 2019Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.